BACKGROUND AND OBJECTIVE As insulin resistance is present in more than 50%of patients without diabetes who have had an ischemic stroke or TIA,addressing this issue seems central to the treatment of these individuals.As one medication,pioglitazone,a peroxisome proliferator-activated receptor y agonist,has been found to reduce the risk of cardiovascular events in patients with type 2 diabetes,this